Akebia Therapeutics, Inc. (AKBA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
AKBA Revenue Growth
Revenue Breakdown (FY 2025)
AKBA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
AKBA Revenue Analysis (2014–2025)
As of May 8, 2026, Akebia Therapeutics, Inc. (AKBA) generated trailing twelve-month (TTM) revenue of $232.4 million, reflecting moderate decline in growth of -6.6% year-over-year. The most recent quarter (Q1 2026) recorded $53.5 million in revenue, down 7.1% sequentially.
Looking at the longer-term picture, AKBA's 5-year compound annual growth rate (CAGR) stands at -4.3%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $335.0 million in 2019.
Revenue diversification analysis shows AKBA's business is primarily driven by License Collaboration And Other Revenue (96%), Supply Agreement (3%), and License Collaboration And Other Revenue, Royalties (1%). With over half of revenue concentrated in License Collaboration And Other Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including FOLD (+20.0% YoY), PTGX (-91.5% YoY), and CYCN (+3.7% YoY), AKBA has underperformed the peer group in terms of revenue growth. Compare AKBA vs FOLD →
AKBA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AKBACurrent | $232M | -6.6% | -4.3% | 9.9% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 PTGX | $46M | -91.5% | +10.0% | -343.6% | |
 CYCN | $2M | +3.7% | -2.0% | -239.8% | |
 ANIP | $883M | +43.8% | +33.5% | 12.6% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% |
AKBA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $236.2M | +47.5% | $196.7M | 83.3% | $23.5M | 9.9% |
| 2024 | $160.2M | -17.7% | $97.0M | 60.6% | $-50,472,000 | -31.5% |
| 2023 | $194.6M | -33.5% | $120.5M | 61.9% | $-46,256,000 | -23.8% |
| 2022 | $292.5M | +38.2% | $270.0M | 92.3% | $-80,779,000 | -27.6% |
| 2021 | $211.7M | -28.2% | $130.2M | 61.5% | $-264,502,000 | -125.0% |
| 2020 | $294.6M | -12.0% | $230.7M | 78.3% | $-377,826,000 | -128.2% |
| 2019 | $335.0M | +61.3% | $189.7M | 56.6% | $-286,288,000 | -85.5% |
| 2018 | $207.7M | +16.7% | $200.1M | 96.3% | $-178,139,000 | -85.8% |
| 2017 | $178.0M | +11495.0% | $177.4M | 99.7% | $-79,917,000 | -44.9% |
| 2016 | $1.5M | - | $-114,250,000 | -7443.0% | $-136,460,000 | -8889.9% |
See AKBA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AKBA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AKBA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAKBA — Frequently Asked Questions
Quick answers to the most common questions about buying AKBA stock.
Is AKBA's revenue growth accelerating or slowing?
AKBA revenue declined -6.6% year-over-year, contrasting with the 5-year CAGR of -4.3%. TTM revenue fell to $232M. This reverses the prior growth trend.
What is AKBA's long-term revenue growth rate?
Akebia Therapeutics, Inc.'s 5-year revenue CAGR of -4.3% reflects the variable expansion pattern. Current YoY growth of -6.6% is below this long-term average.
How is AKBA's revenue distributed by segment?
AKBA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.